GlassScriptPhysician profile
Sanjay Malhotra
NPI 1548280084
$40,772.65
in general payments reported to CMS, 2019-2025
38 companies · $2,428 in 2025
The $2,428 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $4,597 · 2021: $7,022 · 2022: $5,305 · 2023: $1,545 · 2024: $1,658 · 2025: $2,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,615 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,614.76 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16,730.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $9,166.60 | 2019-2025 | Farxiga |
| Biotronik INC. | $2,915.23 | 2019 | |
| Amgen INC. | $1,417.20 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,215.44 | 2019-2025 | |
| Pfizer INC. | $1,071.85 | 2019-2025 | |
| Medtronic, INC. | $1,025.57 | 2021-2025 | Symplicity G3, Ffrangio, Turbohawk |
| Janssen Pharmaceuticals, INC | $953.78 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $671.22 | 2021-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $478.28 | 2019-2025 | |
| Boston Scientific Corporation | $471.95 | 2024-2025 | Watchman Flx, General - Ultrasound, Varithena Administration Pack |
| Medtronic Vascular, INC. | $470.76 | 2019-2020 | |
| Penumbra, INC. | $458.94 | 2019 | |
| Bridgebio Pharma, INC. | $411.37 | 2025 | Attruby |
| Abbott Laboratories | $358.24 | 2019-2025 | Aveir, Cardiomems |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $329.54 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $277.84 | 2021-2025 | Verquvo, Capvaxive |
| Cvrx, INC. | $271.10 | 2021 | |
| Cleerly, INC. | $266.20 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Lexicon Pharmaceuticals, INC. | $262.22 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $212.68 | 2021-2025 | Amvuttra, Onpattro |
| Sanofi-Aventis U.S. LLC | $190.03 | 2019-2024 | |
| Abiomed | $176.18 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.49 | 2019-2023 | |
| Edwards Lifesciences Corporation | $163.11 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Chiesi USA, INC. | $83.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.84 | 2021-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $78.81 | 2019-2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $67.70 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $52.38 | 2022 | |
| Esperion Therapeutics, INC. | $51.37 | 2020-2021 | |
| Amarin Pharma, INC. | $42.47 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $40.78 | 2025 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $40.49 | 2020-2021 | |
| Ethicon US, LLC | $34.03 | 2019 | |
| Biotronik Nro, INC. | $28.32 | 2025 | Prospera |
| Allergan, INC. | $24.09 | 2019 | |
| Novo Nordisk INC | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.